Biogen's rDNA hepatitis B vaccine
Executive Summary
Welcome foundation has licensed rights to the vaccine in "key world markets." With clinicals scheduled for early 1985, Welcome foundation's Welcome Biotechnology will likely be the second company after Merck to enter clinicals with a rDNA produced hepatitis B vaccine. Biogen also licenses the vaccine to Green Cross and an undisclosed third company